Positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro-D-glucose (18F-FDG-PET) has an important role in the management of lymphoma, but it is important to keep in mind that not only lymphoma but also a number of other pathologic and non-pathologic processes can cause increased tissue FDG uptake. Our case is a rare example when a uterine fibroid caused differential diagnostic problem.
Introduction
In the last 10 years positron emission tomography with 2-deoxy-2-[fluorine-18] fluoro-D-glucose (18F-FDG-PET) has emerged as a powerful imaging tool for the detection of various cancers. In high grade lymphoma it helps accurate staging as well as restaging post chemotherapy as it is able to identify nodal and extranodal sites with greater senstivity than computer tomography (CT) alone [1] . Persistent post-chemotherapy masses are common differential diagnostic problems in lymphoma when the level of FDG avidity often provides a clue to clinical management.
Case Report
A 45-year-old woman presented with marked B symptoms, splenomegaly and severe pancytopenia. Her bone marrow trephine biopsy confirmed heavy infiltration of diffuse large B-cell lymphoma; the staging CT scan showed no nodal involvement (stage 4, IPI 2). She went on to have rituximab-cyclophosphamide-doxorubicin-vincristinprednisolon (R-CHOP) chemotherapy resulting in the improvement of her blood counts, the disappearance of her B symptoms and the resolution of the splenomegaly.
At the end of her planned 6 cycles of treatment the bone marrow trephine confirmed remission, and her FDG-PET showed no abnormalities in the regions previously involved, however revealed a highly active (26 × 27 × 30 mm, weight normalized SUVmax: 9.0 g/ml) nodule attached to the uterus (Figure 1 , MIP image). Given that the in addition to persistent lymphoma the differential included leiomyosarcoma hysterectomy was performed. Histopathologically the tumor was highly vascularized uterine leiomyoma (Figure 2 , HE, 250X). No further treatment was utilized, she is alive and well 2 years post chemotherapy. 
Discussion
FDG-PET have radically changed the management of lymphoma. Growing evidence supports its incorporation into clinical decision algorithms, negative interim and end of treatment PET being strong predictors of good outcome in most lymphoma subtypes. As a result of its widespread use, false PET positivity became a common challenge. Examples include infection, post chemo-or radiotherapy inflammation and not uncommonly secondary tumors both benign an malignant [2] [3] [4] .
Uterine fibroid, a benign tumor composed mainly of smooth muscle cells, is typically negative on PET. PET can actually be used to differentiate leiomyomas from leiomyosarcomas [5] . Although this is a rare exception from the normal behavior of uterine fibroids our experience demonstrates that the differential for pelvic FDG avid lesions should include uterine fibroids. 
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